Symbols / EBS $8.29 +3.62% Emergent BioSolutions Inc.
EBS Chart
About
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Fundamentals
Scroll to Statements| Market Cap | 429.18M | Enterprise Value | 807.48M | Income | 52.60M | Sales | 742.90M | Book/sh | 10.03 | Cash/sh | 3.97 |
| Dividend Yield | — | Payout | 0.00% | Employees | 900 | IPO | — | P/E | 8.91 | Forward P/E | 2.77 |
| PEG | 0.38 | P/S | 0.58 | P/B | 0.83 | P/C | — | EV/EBITDA | 3.87 | EV/Sales | 1.09 |
| Quick Ratio | 2.19 | Current Ratio | 5.01 | Debt/Eq | 111.69 | LT Debt/Eq | — | EPS (ttm) | 0.93 | EPS next Y | 2.99 |
| EPS Growth | — | Revenue Growth | -23.60% | Earnings | 2026-04-30 | ROA | 5.33% | ROE | 10.46% | ROIC | — |
| Gross Margin | 49.44% | Oper. Margin | -15.20% | Profit Margin | 7.08% | Shs Outstand | 51.64M | Shs Float | 47.11M | Short Float | 18.98% |
| Short Ratio | 9.54 | Short Interest | — | 52W High | 14.06 | 52W Low | 4.71 | Beta | 2.36 | Avg Volume | 847.05K |
| Volume | 404.00K | Target Price | $12.00 | Recom | None | Prev Close | $8.00 | Price | $8.29 | Change | 3.62% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-09 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-12-16 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-03-21 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-03-04 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-01-21 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-12-30 | init | HC Wainwright & Co. | — → Buy | $15 |
| 2024-11-07 | main | Benchmark | Buy → Buy | $12 |
| 2024-09-13 | reit | Rodman & Renshaw | Buy → Buy | $16 |
| 2024-08-22 | init | Rodman & Renshaw | — → Buy | $16 |
| 2024-08-16 | reit | Benchmark | Buy → Buy | $8 |
| 2024-08-09 | reit | Benchmark | Buy → Buy | $8 |
| 2024-07-03 | reit | Benchmark | Buy → Buy | $8 |
| 2024-07-02 | reit | Benchmark | Buy → Buy | $8 |
| 2024-06-24 | reit | Benchmark | Buy → Buy | $8 |
| 2024-06-21 | reit | Benchmark | Buy → Buy | $8 |
| 2024-06-20 | main | Benchmark | Buy → Buy | $8 |
| 2024-04-11 | reit | Benchmark | Buy → Buy | $5 |
News
RSS: Latest EBS news- How The Reset Price Target Is Shaping The Emergent BioSolutions (EBS) Investment Story - Yahoo Finance Wed, 25 Mar 2026 07
- Emergent BioSolutions will discuss first-quarter results April 30 at 5 p.m. ET - Stock Titan hu, 16 Apr 2026 20
- Emergent BioSolutions (EBS) Stock Fundamentals | Q4 2025: Earnings Fall Short - Fast Rising Picks - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 05
- Emergent (EBS) Q4 2025 Earnings Transcript - The Globe and Mail Wed, 22 Apr 2026 22
- Discipline and Rules-Based Execution in EBS Response - Stock Traders Daily Fri, 03 Apr 2026 14
- $EBS stock is down 15% today. Here's what we see in our data. - Quiver Quantitative Fri, 27 Feb 2026 08
- Emergent BioSolutions Inc (EBS) Stock Price Today & Analysis - Gotrade Mon, 02 Feb 2026 06
- Is Emergent BioSolutions (EBS) Stock Near Support | Price at $8.09, Up 1.63% - Crowd Consensus Signals - UBND thành phố Hải Phòng Mon, 13 Apr 2026 07
- How The Investment Narrative For Emergent BioSolutions (EBS) Is Shifting After The $12 Target Reset - Yahoo Finance ue, 10 Mar 2026 07
- U.S. and foreign governments order $60M in smallpox countermeasures - Stock Titan Wed, 25 Mar 2026 07
- $EBS stock is up 30% today. Here's what we see in our data. - Quiver Quantitative hu, 30 Oct 2025 07
- Only 1 in 10 carry naloxone; Emergent adds NARCAN case - Stock Titan ue, 07 Apr 2026 07
- Emergent BioSolutions Inc.'s (NYSE:EBS) large institutional owners must be happy as stock continues to impress, up 10% over the past week - Yahoo Finance Fri, 26 Sep 2025 07
- Emergent cuts loan costs and pushes debt maturities to 2031 - Stock Titan hu, 16 Apr 2026 20
- Looking for a Fast-paced Momentum Stock at a Bargain? Consider Emergent Biosolutions (EBS) - Yahoo Finance Fri, 07 Nov 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
705.20
-30.43%
|
1,013.60
-0.92%
|
1,023.00
-4.93%
|
1,076.10
|
| Operating Revenue |
|
705.20
-30.43%
|
1,013.60
-0.92%
|
1,023.00
-4.93%
|
1,076.10
|
| Cost Of Revenue |
|
326.20
-52.12%
|
681.30
-3.42%
|
705.40
+1.77%
|
693.10
|
| Reconciled Cost Of Revenue |
|
295.50
-53.65%
|
637.60
-1.29%
|
645.90
+5.94%
|
609.70
|
| Gross Profit |
|
379.00
+14.05%
|
332.30
+4.63%
|
317.60
-17.08%
|
383.00
|
| Operating Expense |
|
266.70
-35.55%
|
413.80
-20.29%
|
519.10
-4.98%
|
546.30
|
| Research And Development |
|
53.20
-24.75%
|
70.70
-36.54%
|
111.40
-40.84%
|
188.30
|
| Selling General And Administration |
|
186.10
-39.58%
|
308.00
-16.40%
|
368.40
+8.51%
|
339.50
|
| Other Operating Expenses |
|
-37.70
-25.67%
|
-30.00
-14.07%
|
-26.30
+36.47%
|
-41.40
|
| Total Expenses |
|
592.90
-45.86%
|
1,095.10
-10.57%
|
1,224.50
-1.20%
|
1,239.40
|
| Operating Income |
|
112.30
+237.79%
|
-81.50
+59.55%
|
-201.50
-23.39%
|
-163.30
|
| Total Operating Income As Reported |
|
100.10
+192.09%
|
-108.70
+85.04%
|
-726.40
-327.29%
|
-170.00
|
| EBITDA |
|
237.90
+544.72%
|
36.90
+107.12%
|
-518.20
-1249.48%
|
-38.40
|
| Normalized EBITDA |
|
262.30
+569.13%
|
39.20
+156.00%
|
-70.00
-120.82%
|
-31.70
|
| Reconciled Depreciation |
|
95.80
-11.95%
|
108.80
-13.03%
|
125.10
-12.70%
|
143.30
|
| EBIT |
|
142.10
+297.64%
|
-71.90
+88.82%
|
-643.30
-254.05%
|
-181.70
|
| Total Unusual Items |
|
-24.40
-960.87%
|
-2.30
+99.49%
|
-448.20
-6589.55%
|
-6.70
|
| Total Unusual Items Excluding Goodwill |
|
-24.40
-960.87%
|
-2.30
+99.49%
|
-448.20
-6589.55%
|
-6.70
|
| Special Income Charges |
|
-24.40
-960.87%
|
-2.30
+99.49%
|
-448.20
-6589.55%
|
-6.70
|
| Other Special Charges |
|
12.20
+2133.33%
|
-0.60
+76.00%
|
-2.50
|
—
|
| Impairment Of Capital Assets |
|
12.20
-55.15%
|
27.20
-94.82%
|
524.90
+7734.33%
|
6.70
|
| Net Income |
|
52.60
+127.60%
|
-190.60
+74.94%
|
-760.50
-259.40%
|
-211.60
|
| Pretax Income |
|
82.80
+157.94%
|
-142.90
+80.46%
|
-731.20
-233.88%
|
-219.00
|
| Net Non Operating Interest Income Expense |
|
-59.30
+16.48%
|
-71.00
+19.23%
|
-87.90
-135.66%
|
-37.30
|
| Interest Expense Non Operating |
|
59.30
-16.48%
|
71.00
-19.23%
|
87.90
+135.66%
|
37.30
|
| Net Interest Income |
|
-59.30
+16.48%
|
-71.00
+19.23%
|
-87.90
-135.66%
|
-37.30
|
| Interest Expense |
|
59.30
-16.48%
|
71.00
-19.23%
|
87.90
+135.66%
|
37.30
|
| Other Income Expense |
|
29.80
+210.42%
|
9.60
+102.17%
|
-441.80
-2301.09%
|
-18.40
|
| Other Non Operating Income Expenses |
|
54.20
+355.46%
|
11.90
+85.94%
|
6.40
+154.70%
|
-11.70
|
| Gain On Sale Of Business |
|
0.00
-100.00%
|
24.30
-67.25%
|
74.20
|
0.00
|
| Tax Provision |
|
30.20
-36.69%
|
47.70
+62.80%
|
29.30
+495.95%
|
-7.40
|
| Tax Rate For Calcs |
|
0.00
+73.81%
|
0.00
+0.00%
|
0.00
+600.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-8.91
-1743.89%
|
-0.48
+99.49%
|
-94.12
-46726.87%
|
-0.20
|
| Net Income Including Noncontrolling Interests |
|
52.60
+127.60%
|
-190.60
+74.94%
|
-760.50
-259.40%
|
-211.60
|
| Net Income From Continuing Operation Net Minority Interest |
|
52.60
+127.60%
|
-190.60
+74.94%
|
-760.50
-259.40%
|
-211.60
|
| Net Income From Continuing And Discontinued Operation |
|
52.60
+127.60%
|
-190.60
+74.94%
|
-760.50
-259.40%
|
-211.60
|
| Net Income Continuous Operations |
|
52.60
+127.60%
|
-190.60
+74.94%
|
-760.50
-259.40%
|
-211.60
|
| Normalized Income |
|
68.09
+136.07%
|
-188.78
+53.55%
|
-406.42
-98.16%
|
-205.10
|
| Net Income Common Stockholders |
|
52.60
+127.60%
|
-190.60
+74.94%
|
-760.50
-259.40%
|
-211.60
|
| Diluted EPS |
|
0.93
+125.83%
|
-3.60
+75.76%
|
-14.85
-232.21%
|
-4.47
|
| Basic EPS |
|
0.98
+127.22%
|
-3.60
+75.76%
|
-14.85
-232.21%
|
-4.47
|
| Basic Average Shares |
|
53.50
+0.94%
|
53.00
+3.52%
|
51.20
+2.20%
|
50.10
|
| Diluted Average Shares |
|
56.70
+6.98%
|
53.00
+3.52%
|
51.20
+2.20%
|
50.10
|
| Diluted NI Availto Com Stockholders |
|
52.60
+127.60%
|
-190.60
+74.94%
|
-760.50
-259.40%
|
-211.60
|
| Amortization |
|
65.10
+0.00%
|
65.10
-0.76%
|
65.60
+9.52%
|
59.90
|
| Amortization Of Intangibles Income Statement |
|
65.10
+0.00%
|
65.10
-0.76%
|
65.60
+9.52%
|
59.90
|
| Depreciation Amortization Depletion Income Statement |
|
65.10
+0.00%
|
65.10
-0.76%
|
65.60
+9.52%
|
59.90
|
| Depreciation And Amortization In Income Statement |
|
65.10
+0.00%
|
65.10
-0.76%
|
65.60
+9.52%
|
59.90
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1,318.60
-5.12%
|
1,389.70
-23.78%
|
1,823.20
-42.42%
|
3,166.30
|
| Current Assets |
|
662.50
+10.66%
|
598.70
-11.89%
|
679.50
-43.86%
|
1,210.40
|
| Cash Cash Equivalents And Short Term Investments |
|
205.40
+106.43%
|
99.50
-10.92%
|
111.70
-82.62%
|
642.60
|
| Cash And Cash Equivalents |
|
205.40
+106.43%
|
99.50
-10.92%
|
111.70
-82.62%
|
642.60
|
| Receivables |
|
84.20
-45.50%
|
154.50
-19.11%
|
191.00
+19.97%
|
159.20
|
| Accounts Receivable |
|
66.80
-50.66%
|
135.40
-4.51%
|
141.80
+38.07%
|
102.70
|
| Gross Accounts Receivable |
|
66.80
-50.66%
|
135.40
-4.51%
|
141.80
+38.07%
|
102.70
|
| Allowance For Doubtful Accounts Receivable |
|
—
|
—
|
—
|
-0.70
|
| Receivables Adjustments Allowances |
|
-0.80
-60.00%
|
-0.50
+77.27%
|
-2.20
-214.29%
|
-0.70
|
| Other Receivables |
|
18.20
-7.14%
|
19.60
-61.87%
|
51.40
-10.14%
|
57.20
|
| Inventory |
|
343.40
+10.17%
|
311.70
-5.23%
|
328.90
-6.22%
|
350.70
|
| Raw Materials |
|
120.60
+25.76%
|
95.90
-25.49%
|
128.70
-9.56%
|
142.30
|
| Work In Process |
|
109.00
+26.30%
|
86.30
-23.83%
|
113.30
-2.50%
|
116.20
|
| Finished Goods |
|
113.80
-12.12%
|
129.50
+49.02%
|
86.90
-5.75%
|
92.20
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
3.70
-39.34%
|
6.10
|
0.00
|
0.00
|
| Other Current Assets |
|
25.80
-4.09%
|
26.90
-43.84%
|
47.90
-17.27%
|
57.90
|
| Total Non Current Assets |
|
656.10
-17.05%
|
791.00
-30.84%
|
1,143.70
-41.53%
|
1,955.90
|
| Net PPE |
|
205.40
-24.09%
|
270.60
-29.31%
|
382.80
-53.18%
|
817.60
|
| Gross PPE |
|
509.50
-23.69%
|
667.70
-15.93%
|
794.20
-33.89%
|
1,201.40
|
| Accumulated Depreciation |
|
-304.10
+23.42%
|
-397.10
+3.48%
|
-411.40
-7.19%
|
-383.80
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
20.70
-19.77%
|
25.80
-14.00%
|
30.00
-45.36%
|
54.90
|
| Buildings And Improvements |
|
160.50
-18.15%
|
196.10
-14.70%
|
229.90
-29.89%
|
327.90
|
| Machinery Furniture Equipment |
|
321.70
-26.13%
|
435.50
-12.48%
|
497.60
-21.40%
|
633.10
|
| Construction In Progress |
|
6.60
-35.92%
|
10.30
-71.93%
|
36.70
-80.22%
|
185.50
|
| Goodwill And Other Intangible Assets |
|
436.50
-12.96%
|
501.50
-11.49%
|
566.60
-40.17%
|
947.00
|
| Goodwill |
|
—
|
—
|
0.00
-100.00%
|
218.20
|
| Other Intangible Assets |
|
436.50
-12.96%
|
501.50
-11.49%
|
566.60
-22.26%
|
728.80
|
| Other Non Current Assets |
|
14.20
-24.87%
|
18.90
-90.27%
|
194.30
+1.57%
|
191.30
|
| Total Liabilities Net Minority Interest |
|
796.00
-12.23%
|
906.90
-22.74%
|
1,173.90
-34.00%
|
1,778.60
|
| Current Liabilities |
|
132.20
-18.60%
|
162.40
-75.07%
|
651.30
-47.00%
|
1,228.90
|
| Payables And Accrued Expenses |
|
74.60
-11.61%
|
84.40
-35.47%
|
130.80
-5.49%
|
138.40
|
| Payables |
|
62.40
-6.45%
|
66.70
-40.55%
|
112.20
+8.41%
|
103.50
|
| Accounts Payable |
|
55.60
-8.70%
|
60.90
-45.72%
|
112.20
+8.41%
|
103.50
|
| Current Accrued Expenses |
|
12.20
-31.07%
|
17.70
-4.84%
|
18.60
-46.70%
|
34.90
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
41.80
-25.49%
|
56.10
-24.29%
|
74.10
-15.12%
|
87.30
|
| Total Tax Payable |
|
6.80
+17.24%
|
5.80
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
413.70
-56.78%
|
957.30
|
| Current Debt |
|
—
|
—
|
413.70
-56.78%
|
957.30
|
| Other Current Liabilities |
|
15.80
-27.85%
|
21.90
-33.03%
|
32.70
-28.76%
|
45.90
|
| Total Non Current Liabilities Net Minority Interest |
|
663.80
-10.84%
|
744.50
+42.46%
|
522.60
-4.93%
|
549.70
|
| Long Term Debt And Capital Lease Obligation |
|
572.10
-13.80%
|
663.70
+48.65%
|
446.50
-0.45%
|
448.50
|
| Long Term Debt |
|
572.10
-13.80%
|
663.70
+48.65%
|
446.50
-0.45%
|
448.50
|
| Non Current Deferred Liabilities |
|
37.80
-9.35%
|
41.70
-11.65%
|
47.20
-20.94%
|
59.70
|
| Non Current Deferred Revenue |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
37.80
-9.35%
|
41.70
-11.65%
|
47.20
-20.94%
|
59.70
|
| Other Non Current Liabilities |
|
53.90
+37.85%
|
39.10
+35.29%
|
28.90
-30.36%
|
41.50
|
| Stockholders Equity |
|
522.60
+8.24%
|
482.80
-25.64%
|
649.30
-53.21%
|
1,387.70
|
| Common Stock Equity |
|
522.60
+8.24%
|
482.80
-25.64%
|
649.30
-53.21%
|
1,387.70
|
| Capital Stock |
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
|
| Common Stock |
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
60.80
+1.45%
|
59.93
+3.68%
|
57.80
+3.77%
|
55.70
|
| Ordinary Shares Number |
|
52.10
-4.10%
|
54.33
+4.08%
|
52.20
+4.19%
|
50.10
|
| Treasury Shares Number |
|
8.70
+55.36%
|
5.60
+0.00%
|
5.60
+0.00%
|
5.60
|
| Additional Paid In Capital |
|
942.40
+1.55%
|
928.00
+2.61%
|
904.40
+3.54%
|
873.50
|
| Retained Earnings |
|
-159.80
+24.76%
|
-212.40
-874.31%
|
-21.80
-102.95%
|
738.70
|
| Gains Losses Not Affecting Retained Earnings |
|
-7.50
-44.23%
|
-5.20
+8.77%
|
-5.70
-283.87%
|
3.10
|
| Treasury Stock |
|
252.60
+10.94%
|
227.70
+0.00%
|
227.70
+0.00%
|
227.70
|
| Other Equity Adjustments |
|
-7.50
-44.23%
|
-5.20
+8.77%
|
-5.70
-283.87%
|
3.10
|
| Total Equity Gross Minority Interest |
|
522.60
+8.24%
|
482.80
-25.64%
|
649.30
-53.21%
|
1,387.70
|
| Total Capitalization |
|
1,094.70
-4.52%
|
1,146.50
+4.63%
|
1,095.80
-40.32%
|
1,836.20
|
| Working Capital |
|
530.30
+21.54%
|
436.30
+1447.16%
|
28.20
+252.43%
|
-18.50
|
| Invested Capital |
|
1,094.70
-4.52%
|
1,146.50
-24.05%
|
1,509.50
-45.96%
|
2,793.50
|
| Total Debt |
|
572.10
-13.80%
|
663.70
-22.84%
|
860.20
-38.81%
|
1,405.80
|
| Net Debt |
|
366.70
-35.01%
|
564.20
-24.62%
|
748.50
-1.93%
|
763.20
|
| Net Tangible Assets |
|
86.10
+560.43%
|
-18.70
-122.61%
|
82.70
-81.23%
|
440.70
|
| Tangible Book Value |
|
86.10
+560.43%
|
-18.70
-122.61%
|
82.70
-81.23%
|
440.70
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
170.60
+190.63%
|
58.70
+128.45%
|
-206.30
-504.99%
|
-34.10
|
| Cash Flow From Continuing Operating Activities |
|
170.60
+190.63%
|
58.70
+128.45%
|
-206.30
-504.99%
|
-34.10
|
| Net Income From Continuing Operations |
|
52.60
+127.60%
|
-190.60
+74.94%
|
-760.50
-259.40%
|
-211.60
|
| Depreciation Amortization Depletion |
|
95.80
-11.95%
|
108.80
-13.03%
|
125.10
-12.70%
|
143.30
|
| Depreciation |
|
30.70
-29.75%
|
43.70
-26.55%
|
59.50
-28.66%
|
83.40
|
| Amortization Cash Flow |
|
65.10
+0.00%
|
65.10
-0.76%
|
65.60
+9.52%
|
59.90
|
| Depreciation And Amortization |
|
95.80
-11.95%
|
108.80
-13.03%
|
125.10
-12.70%
|
143.30
|
| Amortization Of Intangibles |
|
65.10
+0.00%
|
65.10
-0.76%
|
65.60
+9.52%
|
59.90
|
| Other Non Cash Items |
|
10.20
-29.66%
|
14.50
+8.21%
|
13.40
+41.05%
|
9.50
|
| Stock Based Compensation |
|
16.20
-10.00%
|
18.00
-22.08%
|
23.10
-48.78%
|
45.10
|
| Asset Impairment Charge |
|
12.20
-55.15%
|
27.20
-94.82%
|
524.90
+7734.33%
|
6.70
|
| Deferred Tax |
|
-4.00
+27.27%
|
-5.50
+38.20%
|
-8.90
+68.88%
|
-28.60
|
| Deferred Income Tax |
|
-4.00
+27.27%
|
-5.50
+38.20%
|
-8.90
+68.88%
|
-28.60
|
| Operating Gains Losses |
|
10.00
+516.67%
|
-2.40
+95.48%
|
-53.10
-1575.00%
|
3.60
|
| Gain Loss On Investment Securities |
|
5.50
+400.00%
|
1.10
|
—
|
—
|
| Change In Working Capital |
|
-22.40
-125.25%
|
88.70
+226.17%
|
-70.30
-3247.62%
|
-2.10
|
| Change In Receivables |
|
25.50
+204.51%
|
-24.40
-12.96%
|
-21.60
-118.29%
|
118.10
|
| Changes In Account Receivables |
|
25.50
+204.51%
|
-24.40
-12.96%
|
-21.60
-118.29%
|
118.10
|
| Change In Inventory |
|
-30.30
-23.67%
|
-24.50
-4183.33%
|
0.60
+101.05%
|
-57.10
|
| Change In Prepaid Assets |
|
11.70
-93.11%
|
169.90
+1352.14%
|
11.70
+158.79%
|
-19.90
|
| Change In Payables And Accrued Expense |
|
-35.90
+7.71%
|
-38.90
+29.91%
|
-55.50
+31.90%
|
-81.50
|
| Change In Accrued Expense |
|
-27.50
-366.10%
|
-5.90
+91.07%
|
-66.10
+2.07%
|
-67.50
|
| Change In Payable |
|
-8.40
+74.55%
|
-33.00
-411.32%
|
10.60
+175.71%
|
-14.00
|
| Change In Account Payable |
|
-8.40
+74.55%
|
-33.00
-411.32%
|
10.60
+175.71%
|
-14.00
|
| Change In Other Working Capital |
|
6.60
+0.00%
|
6.60
+220.00%
|
-5.50
-114.36%
|
38.30
|
| Investing Cash Flow |
|
69.40
-44.57%
|
125.20
-41.03%
|
212.30
+155.68%
|
-381.30
|
| Cash Flow From Continuing Investing Activities |
|
69.40
-44.57%
|
125.20
-41.03%
|
212.30
+155.68%
|
-381.30
|
| Net PPE Purchase And Sale |
|
24.40
+262.67%
|
-15.00
+70.93%
|
-51.60
+55.44%
|
-115.80
|
| Purchase Of PPE |
|
-13.80
+39.74%
|
-22.90
+55.62%
|
-51.60
+55.44%
|
-115.80
|
| Sale Of PPE |
|
38.20
+383.54%
|
7.90
|
0.00
|
0.00
|
| Capital Expenditure |
|
-13.80
+39.74%
|
-22.90
+55.62%
|
-51.60
+55.44%
|
-115.80
|
| Net Business Purchase And Sale |
|
0.00
-100.00%
|
110.20
-59.22%
|
270.20
|
0.00
|
| Gain Loss On Sale Of Business |
|
0.00
+100.00%
|
-32.20
+56.60%
|
-74.20
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
-21.80
|
| Purchase Of Intangibles |
|
—
|
—
|
—
|
-21.80
|
| Net Other Investing Changes |
|
45.00
+50.00%
|
30.00
+576.19%
|
-6.30
+97.63%
|
-265.50
|
| Financing Cash Flow |
|
-136.60
+28.11%
|
-190.00
+64.53%
|
-535.70
-211.33%
|
481.20
|
| Cash Flow From Continuing Financing Activities |
|
-136.60
+28.11%
|
-190.00
+64.53%
|
-535.70
-211.33%
|
481.20
|
| Net Issuance Payments Of Debt |
|
-108.70
+45.21%
|
-198.40
+63.49%
|
-543.40
-196.31%
|
564.20
|
| Issuance Of Debt |
|
0.00
-100.00%
|
284.00
+1320.00%
|
20.00
-96.66%
|
598.00
|
| Repayment Of Debt |
|
-108.70
+77.47%
|
-482.40
+14.38%
|
-563.40
-1566.86%
|
-33.80
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
284.00
+1320.00%
|
20.00
-96.66%
|
598.00
|
| Long Term Debt Payments |
|
-108.70
+77.47%
|
-482.40
+14.38%
|
-563.40
-1566.86%
|
-33.80
|
| Net Long Term Debt Issuance |
|
-108.70
+45.21%
|
-198.40
+63.49%
|
-543.40
-196.31%
|
564.20
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
598.00
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
598.00
|
| Net Common Stock Issuance |
|
-24.90
-367.74%
|
9.30
+10.71%
|
8.40
+110.23%
|
-82.10
|
| Common Stock Payments |
|
-24.90
|
0.00
|
0.00
+100.00%
|
-82.10
|
| Repurchase Of Capital Stock |
|
-24.90
|
0.00
|
0.00
+100.00%
|
-82.10
|
| Proceeds From Stock Option Exercised |
|
2.20
-85.23%
|
14.90
+727.78%
|
1.80
-64.00%
|
5.00
|
| Net Other Financing Charges |
|
-5.20
+67.09%
|
-15.80
-532.00%
|
-2.50
+57.63%
|
-5.90
|
| Changes In Cash |
|
103.40
+1795.08%
|
-6.10
+98.85%
|
-529.70
-905.02%
|
65.80
|
| Effect Of Exchange Rate Changes |
|
0.10
|
0.00
+100.00%
|
-1.20
-340.00%
|
0.50
|
| Beginning Cash Position |
|
105.60
-5.46%
|
111.70
-82.62%
|
642.60
+11.50%
|
576.30
|
| End Cash Position |
|
209.10
+98.01%
|
105.60
-5.46%
|
111.70
-82.62%
|
642.60
|
| Free Cash Flow |
|
156.80
+337.99%
|
35.80
+113.88%
|
-257.90
-72.05%
|
-149.90
|
| Interest Paid Supplemental Data |
|
49.70
-22.34%
|
64.00
-6.30%
|
68.30
+106.97%
|
33.00
|
| Income Tax Paid Supplemental Data |
|
40.00
+50.94%
|
26.50
-49.81%
|
52.80
+751.61%
|
6.20
|
| Common Stock Issuance |
|
0.00
-100.00%
|
9.30
+10.71%
|
8.40
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
9.30
+10.71%
|
8.40
|
0.00
|
| Sale Of Business |
|
0.00
-100.00%
|
110.20
-59.22%
|
270.20
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-17 View
- 42026-04-03 View
- 42026-03-06 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 8-K2026-03-03 View
- 10-K2026-02-27 View
- 8-K2026-02-26 View
- 42026-02-10 View
- 42026-02-10 View
- 42026-02-10 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|